Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Nimotuzumab by InnoMab for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Nimotuzumab is under clinical development by InnoMab and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...